Navigation Links
YM BioSciences reports second quarter 2010 operational and financial results
Date:2/8/2010

5,123 Deficit (153,130,276) (146,251,951) ----------------------------------------------------------------------- 33,403,279 39,704,325 Basis of presentation Commitments Subsequent event ------------------------------------------------------------------------- $ 39,041,215 $ 46,069,936 ------------------------------------------------------------------------- ------------------------------------------------------------------------- YM BIOSCIENCES INC. Interim Consolidated Statements of Operations and Comprehensive Income and Deficit (Expressed in Canadian dollars, unless otherwise indicated) ------------------------------------------------------------------------- Three months ended Six months ended December 31, December 31, 2009 2008 2009 2008 ------------------------------------------------------------------------- (Unaudited) (Unaudited) Out-licensing revenue $ 697,583 $ 1,832,224 $ 1,425,121 $ 3,047,169 Interest income 13,174 365,067 32,293 807,688 ------------------------------------------------------------------------- 710,757 2,197,291 1,457,414 3,854,857 Expenses: Licensing and product development 2,372,946 4,421,428 4,808,994 8,266,612 General and adminis- trative 1,699,330 1,193,209 3,483,762 2,340,587 ----------------------------------------------------------------------- 4,072,276 5,614,637 8,292,756 10,607,199 -----------------------
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
3. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
4. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
5. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
6. YM BioSciences announces result of Cytopia shareholder vote
7. Profectus Biosciences to Present at Key Investor Conference in January 2010
8. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
9. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
10. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
11. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... CORAL SPRINGS, Florida , September 19, 2014 /PRNewswire/ ... biotech companies release latest developments, patents and results of ... (OTC: GNSZ), Eli Lilly and Company (NYSE: ... ), Celgene Corporation (NASDAQ: CELG ) and ... (OTCQB: GNSZ), a leader in developing prodrug therapeutics for ...
(Date:9/19/2014)... , September 19, 2014 ... 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... science and medical research in the field of growth  ... KGaA, Darmstadt, Germany , today announced ... (GGI) for 2014. The awards were announced during a ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... 18, 2014 ... ) has announced the addition of ... Strategic Business Report" report to ... report analyzes the worldwide markets for ... the following Product Segments: Polymeric Materials, ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... BIRMINGHAM, Ala., Sept. 19 BioCryst,Pharmaceuticals, Inc. ... findings,from a Phase II study with intramuscular ... for the treatment of seasonal and,life-threatening influenza. ... The study was a randomized, double-blind, placebo-controlled ...
... ,Arpida Ltd (SWX: ARPN) presented a large body ... iclaprim at the 47th annual Interscience,Conference on Antimicrobial ... major scientific conference where thousands of scientists and,clinicians ... the latest,developments in the field of infectious diseases. ...
... bacterial contamination in ... platelets, WORCESTER, ... for detecting bacterial contaminants in,blood cells and tissue, has received 510 (k) ... Administration (FDA). This provides,Verax authorization to market the device, which cuts the ...
Cached Biology Technology:BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 2Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 3Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 4Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 2Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 3
(Date:9/18/2014)... International Space Station ever starts a "frequent flyers" program, ... Recently the orbiting laboratory has hosted increasing numbers of ... from the space station in April, and another is ... experiment is planned to launch in December. , Fruit ... the world-- and in space. Model organisms can reveal ...
(Date:9/18/2014)... DNA, tiny strands of nucleic acid that contain instructions ... genetic data, our DNA is copied into RNA molecules, ... tasks in our cells. , Several years ago, ... all other known RNAs, this molecule is circular, and ... little has been known about how they are produced. ...
(Date:9/18/2014)... Dogs generally seem to be cheerful, happy-go-lucky characters, so ... outlook on life. , In fact some dogs ... University of Sydney shows. , "This research is ... in dogs objectively and non-invasively. It offers researchers and ... and how that changes," said Dr Melissa Starling, from ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Dogs can be pessimists too 2Dogs can be pessimists too 3
... worldwide battle to curtail malaria, one of the most prevalent ... drug has fallen by the wayside as the malaria parasite ... sweet wormwood plant, Artemisia annua , remains as an ... combined with other antimalarial medications to make it less prone ...
... Valley, NY. (Dec. 20, 2012) When different types ... them aid in repairing central nervous system (CNS) trauma, ... A Belgian research team carried out research aimed at ... cells - neural stem cells, mouse embryonic fibroblasts, dendritic ...
... have developed a statistical explanation for why some things are ... "We,ve built the first mathematical model that uses a bird,s ... Emory biologist Samuel Sober. "We hope it will help us ... Sober conducted the research with physiologist Michael Brainard of ...
Cached Biology News:New whole plant therapy shows promise as an effective and economical treatment for malaria 2New whole plant therapy shows promise as an effective and economical treatment for malaria 3New whole plant therapy shows promise as an effective and economical treatment for malaria 4Cell Transplantation study investigates fate and function of cells transplanted to the CNS 2Doing the math for how songbirds learn to sing 2
Human sIL-2R/CD25 ELI-PAIR Kit...
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: